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To compare irinotecan (CPT-11)þgemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell
lung cancer (NSCLC) progressing after docetaxel–cisplatinum-based therapy. A total of 147 evaluable, pretreated patients, with
NSCLC, received either gemcitabine (1000mgm
 2, days 1 and 8)þCPT-11 (300mgm
 2, day 8) (Group A, n¼76) or CPT-11
(300mgm
 2, day 1) (Group B, n¼71), every 3 weeks. All patients were evaluable for response and toxicity. The objective response
rate was 18.4% (95% CI: 9.71–27.14%) and 4.2% (95% CI: 0–8.90%) (P¼0.009) for groups A and B, respectively. No significant
differences between the two groups in terms of the median duration of response, time to tumour progression, overall survival and 1-
year survival were observed. The CPT-11/gemcitabine regimen significantly improved the patients’ quality of life (‘general mood
today’ (P¼0.014), ‘coughing’ (P¼0.003) and ‘intensity of symptoms’ (P¼0.034)) compared with CPT-11. More cycles had to be
delayed (P¼0.001) and required prophylactic growth factor support (P¼0.001) in Group A than B. Three (3.9%) patients in Group
A and eight (11.3%) in Group B developed febrile neutropenia (P¼0.09); one patient died of sepsis in each group. Three additional
(Group A, n¼1; Group B, n¼2) treatment-related deaths were observed. Grade 3–4 haematologic toxicity was comparable in the
two groups except anaemia (P¼0.03 in favour of CPT-11). Other nonhaematologic toxicities were mild and similar in the two
groups. CPT-11þgemcitabine resulted in a higher response rate and better control of disease-related symptoms than CPT-11 alone,
but without any improvement in the overall survival.
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Cisplatin-based chemotherapy confers a survival advantage and
still represents the standard of care in inoperable locally advanced
and metastatic non-small-cell lung cancer (NSCLC) (Souquet et al,
1993; NSCLC Collaborative Group, 1995) and its use is increased as
front-line treatment (Belani, 1993) therefore, a higher proportion
of patients are becoming candidates for second-line chemotherapy.
Several phase II studies have shown that some newer drugs
either alone or in combination might be active in the second-line
setting (Fossella et al, 1997; Androulakis et al, 1998; Ferrigno and
Buccheri, 2000; Huisman et al, 2000; Iaffaioli et al, 2000).
Randomised studies demonstrated that second-line docetaxel
conferred survival and clinical benefit as well as improved quality
of life compared with best supportive care (Shepherd et al, 2000)
or monotherapy with vinorelbine or ifosfamide (Fossella et al,
2000). Also, the pyrimidine antimetabolite gemcitabine has
demonstrated significant activity in pretreated patients with
advanced NSCLC, with objective responses ranging from 7 to
20%, and a median survival of 22–36 weeks (Baas et al, 1999;
Crino et al, 1999; Reddy et al, 1999; Rossi et al, 1999). The data for
irinotecan (CPT-11), a semisynthetic derivative of the plant
alkaloid camptothecin (Kunimoto et al, 1987), are conflicting. In
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lone study, CPT-11 failed to demonstrate any antitumour activity in
26 pretreated patients with NSCLC, whereas in another an overall
response rate of 14% was achieved (Ferrigno and Buccheri, 2000).
Gemcitabine and CPT-11 have shown synergistic in vitro activity
(Pei et al, 1997; Schwartz et al 2001). Their combination is both
feasible and well tolerated (Lima et al, 1998; O’Reilly et al, 1999;
Kakolyris et al, 2002). In a phase I study, it was revealed that the
main dose-limiting events of the gemcitabine and CPT-11
combination given in a 3-weekly schedule were grade 4 thrombo-
cytopenia, grade 3 diarrhoea and grade 3 asthenia (Kakolyris et al,
2002). In a pilot phase II study, where gemcitabine was used at a dose
of 1000mgm
 2 in order to reduce the incidence of thrombocyto-
penia, we observed five PRs among 23 pretreated patients with
docetaxel and cisplatin. The main toxicities included grade 3–4
diarrhoea in 20% and grade 3–4 neutropenia in 53% of the cycles.
As a consequence of the promising activity demonstrated by
CPT-11 in combination with gemcitabine, we conducted a
prospective, multicentre, randomised phase II study to compare
the efficacy and tolerance of this regimen with that of CPT-11
monotherapy. CPT-11 monotherapy was chosen for the second
arm for the following reasons: (i) all patients were pretreated with
docetaxel and platinum; and (ii) to more appropriately evaluate
the antitumour activity of CPT-11 in the second-line setting.
PATIENTS AND METHODS
Patients
Patients (aged X18 years) with WHO performance status (PS) 0–2
and stage IIIB or IV, cytologically or histologically confirmed
NSCLC, were enrolled into this trial. Patients progressing either
under docetaxel/platinum (cisplatin or carboplatin) chemotherapy
or after its completion were eligible for randomisation. The
additional inclusion criteria were: at least one bidimensionally
measurable lesion outside an irradiation field; adequate bone,
kidney and liver function (with the exception of alkaline
phosphatase, which could be up to five times the UNL in case of
liver metastases). Prior radiotherapy was allowed, provided that it
had been completed at least 4 weeks prior to enrolment and p25%
of the bone marrow had been irradiated; at least 4 weeks had to
have elapsed from completion of the last cycle of front-line
chemotherapy. Patients were excluded if there was severe
cardiopulmonary insufficiency, a positive pregnancy test for
women of child-bearing age, severe angina pectoris or a recent
myocardial infarction, active infection or severe malnutrition (loss
of 415% of body weight). All patients had to provide written,
informed consent. The trial was approved by the Ethics and
Scientific Committees of the participating institutions.
Treatment plan and dose modifications
Eligible patients were stratified according to their PS (WHO 0–1 vs
2) and their best response to docetaxel/platinum first-line
chemotherapy (CRþPR vs SDþPD); patients were randomised
centrally to receive either gemcitabine (Gemzar
s, Elli Lilly,
Indianapolis, USA), 1000mgm
 2, as a 30-min intravenous (i.v.)
infusion on days 1 and 8 and CPT-11 (Campto
s, Aventis Pharma,
Bridgewater, USA) 300mgm
 2, as a 60-min i.v. infusion on day 8,
following the gemcitabine administration (Group A) or CPT-11 at
the same dose on day 1 (Group B). Cycles were repeated every 3
weeks. All patients received prophylactic antiemetic therapy
(odansetron 16mgþdexamethasone 8mg, given i.v.). Delayed
diarrhoea due to CPT-11 was treated with loperamide.
Dose modifications were performed according to the haemato-
logical and gastrointestinal toxicity. Patients developing grade 3–4
neutropenia without fever received the subsequent cycles with
prophylactic recombinant human-granulocyte colony-stimulating
factor (rhG-CSF: Granocyte, Aventis Pharma) (150mgm
 2,d 9–
d15). If grade 3–4 neutropenia recurred despite prophylactic rhG-
CSF or febrile neutropenia (fever 437.51C for at least 24h with
neutropenia grade 3–4) developed, the d8 doses of both drugs were
reduced by 25% for all subsequent cycles. Patients with grade 4
thrombocytopenia were treated in subsequent cycles with a 25%
reduction of the gemcitabine dose. Patients who presented with
grade 3–4 delayed diarrhoea were treated in all subsequent cycles
with a 25% reduction of the CPT-11 dose. Patients requiring more
than one dose reduction were withdrawn from the study.
Baseline and follow-up assessments
Baseline assessments included complete medical history and
physical examination, complete blood cell count with differential
and serum chemistry. Bidimensionally measurable lesions were
determined by standard imaging procedures at baseline (chest X-
ray, ultrasound, CT scans of the thorax, abdomen and brain,
magnetic resonance imaging and whole body bone scan). Tumour
assessments for response were performed every three chemother-
apy cycles. Complete medical history and physical examinations,
as well as complete blood cell count with differential and serum
chemistry, were performed every 3 weeks. Chest X-rays were
performed every two chemotherapy cycles. Treatment-related
haematological toxicity was evaluated twice a week and daily in
patients with grade 3–4 neutropenia or thrombocytopenia.
Patients who received at least three cycles of chemotherapy were
assessed for response according to the WHO criteria (WHO, 1979).
All responses, which had to be maintained for at least 4 weeks,
were confirmed by an independent panel of radiologists. Patients
who received at least one chemotherapy cycle were assessable for
toxicity (WHO, 1979).
For the quality of life assessment, the Lung Cancer Symptom
Scale (LCSS) and the EuroQOL (EQ-5D) questionnaire were used
at baseline and every three chemotherapy cycles thereafter (Hollen
et al, 1993; Rabin and de Charro, 2001).
Statistical considerations
This was a prospective, multicentre, randomised phase II trial. The
primary end point was the comparison of the median survivals for
the two groups. Secondary end points included objective tumour
response rates, duration of response, time to progression (TTP),
treatment tolerance and quality of life. For the sample size
calculation, a median survival of 9 and 5 months for Groups A and
B, respectively, was assumed. A total of 72 patientsarm
 1 were
required in order that the study has significant difference (at the
5% level) between the two survival curves with a power of 90%.
Differences of rates between groups were assessed by Pearson’s
w
2 test or Fisher’s test where appropriate. Time-to-event end points
were calculated using Kaplan–Meier methods with appropriate
censoring (Collet, 1999). The independent influence of several
factors on the risk of nonresponse, relapse or nonsurvival was
assessed by logistic regression, while that on the hazards of relapse
or failure of survival by Cox’s proportional-hazards model.
Survival was calculated from the date of randomisation to
second-line chemotherapy until the date of death. Time to disease
progression was assessed from the date of randomisation until the
date of disease progression. Response duration was calculated
from the date that the criteria of response were met for the first
time until the date of documentation of disease progression.
RESULTS
Patient demographics
From August 1999 to April 2002, 154 pretreated patients with
NSCLC were registered and randomised to receive either CPT-11/
CPT-11 with or without gemcitabine second-line in NSCLC
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lgemcitabine (Group A, n¼79) or CPT-11 (Group B, n¼75). Three
patients in Group A (two never received chemotherapy and one
because of a major protocol violation) and four patients in Group
B (two never received chemotherapy, one was treated with RT
because of superior vena cava syndrome and one for a major
protocol violation) were not evaluable. The baseline patient
characteristics are presented in Table 1. The two groups were well
balanced with respect to gender, PS, histology and extension of the
disease.
Response to treatment
In total, 76 patients in Group A and 71 patients in Group B were
assessed for response. Three Group A and two Group B patients
were not evaluable, but were considered as progressors in the
intention-to-treat analysis. In all, 14 PRs (ORR¼18.4%; 95% CI:
9.7–27.1%) were observed in Group A and one (1.4%) CR and two
(2.8%) PRs (ORR¼4.2%; 95% CI: 0–8.9%) in Group B (P¼0.009;
Table 2). A total of 20 (26.3%) Group A and 18 (25.3%) Group B
patients had SD, while 42 (55.3%) and 50 (70.4%) Group A and B
patients, respectively, had PD. The risk of nonresponse (SDþPD)
among Group B patients was about four times (odds ration: 3.902;
95% CI: 1.032–14.75) that of Group A; conversely, age, gender, PS,
histology or number of involved sites had no significant effect on
the risk of nonresponse. Of the 14 responders in Group A, three
had experienced a PR, six SD and five PD on first-line
chemotherapy. Of the three responders in Group B, one had a
PR, one SD and one PD on front-line chemotherapy. The objective
response rate for CPT-11/gemcitabine was significantly higher
than that for CPT-11 alone in the lung (18 vs 5%; P¼0.017), liver
(33 vs 0%; P¼0.031) and lymph nodes (27 vs 6%; P¼0.031). The
median duration of response was 5.5 and 4 months in Groups A
and B, respectively (Table 2).
The median interval from the last first-line chemotherapy
treatment for responders vs nonresponders in Group A was 1.25
(range 1–29) and 3 (range 1–24) months, respectively (P¼0.314);
in Group B patients, the corresponding values were 1 (range, 1–6)
and 3 (range, 1–42) months, respectively (P¼0.315).
Out of 34 Group A and 17 (81%) out of 21 Group B patients, 27
(79.4%)who had CR, PR and SD during treatment had disease
recurrence during the follow-up period (P¼0.890). The median
TTP was 7.5 (range, 2.5–19) and 5.0 (range, 1.0–15.5) months for
Group A and B patients, respectively (P¼0.346; Table 2). A total of
21 (28%) and 15 (21.1%) patients in Groups A and B, respectively,
received third-line chemotherapy. The median overall survival of
patients who received third-line chemotherapy was 10 (range, 2.5–
29) months compared with 6 (range, 0.5–24) months survival of
patients who did not received further treatment (log-rank test:
P¼0.0065).
Survival
The median follow-up period was 7.5 (range, 0.5–29) months for
Group A and 6.5 (range, 0.5–24) months for Group B patients. A
total of 54 (71%) Group A and 53 (75%) Group B patients died
(P¼0.625). The causes of death were disease progression (Group
A, n¼50; Group B, n¼49), treatment-related toxicity (Group A,
n¼2; Group B, n¼3) and nontreatment-related reasons (Group
A: one patient with pulmonary embolism and one patient with
postorthopedic haemorrhage; Group B: one with myocardial
infarction and one with bowel obstruction).
Table 1 Patient characteristics
CPT-11/GEM (Group A) CPT-11 (Group B)
No. of patients % No. of patients %
Patients randomised 79 75
Evaluable for toxicity 76 71
Evaluable for response 76 71
Gender
Male 71 93 63 89
Female 5 7 8 11
Age (years)
Median (range) 60.5 (42–72) 64 (42–72)
Performance status (WHO)
0–1 69 91 64 90
27 9 7 1 0
Histology
Adenocarcinomas 25 33 24 34
Nonadenocarcinomas 51 67 47 66
Stage
i.v. 76 100 71 100
No. of organs involved
12 8 3 7 2 8 4 0
23 2 4 2 3 3 4 7
X31 6 2 1 1 0 1 3
Prior treatment
Radiotherapy 12 15 17 23
Chemotherapy 100 100 100 100
Platinum compound
CDDP 59 78 58 82
Carboplatin 17 22 13 18
Best response to first-line chemoTx
CR/PR 27 36 19 27
SD/PD 49 64 52 73
WHO¼World Health Organisation; i.v.¼intravenous; CPT-11¼irinotecan;
GEM¼gemcitabine; CDDP¼cisplatin; CR¼complete response; PR¼partial re-
sponse; SD¼stable disease; PD¼progressive disease.
Table 2 Efficacy of CPT-11+GEM regimen and CPT-11 alone as
second-line treatment of NSCLC patients pretreated with docetaxel and
CDDP
CPT-11+GEM
(Group A)
CPT-11
(Group B) P-value
CR — 1 (1.4%)
PR 14 (18.4%) 2 (2.8%)
ORR (CR+PR) 14 (18.4%) 3 (4.2%) 0.009
a
(95% CI) 9.71–27.14%  0.45–8.90%
SD 20 (26.3%) 18 (25.3%)
PD 42 (55.3%) 50 (70.4%)
Duration of response (mo)
Median (range) 5.5 (2–14) 4.0 (2–12) 0.885
Time to progression (mo)
Median (range) 7.5 (2.5–19) 5.0 (1.0–15.5) 0.346
Survival (mo)
Median (range) 9.0 (0.5–29) 7.0 (0.5–24) 0.589
1-year survival (%) 24.5 29
NSCLC¼non-small-cell lung cancer; mo¼months; CI¼confidence interval.
aFisher’s
exact test.
CPT-11 with or without gemcitabine second-line in NSCLC
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Group A and 7 (range, 0.5–24) months in Group B patients
(P¼0.589; Figure 1, Table 2). The 1-year survival rates were 24.5
and 29% for Group A and B patients. Taken all patients together,
survival was significantly affected by the PS (P¼0.047) but not by
the age, gender, tumour histology or number of involved sites.
Overall, the median survival among patients with PS 0–1 was 8
(range, 0.5–29) months compared to 1.5 (range 0.5–23) months
for patients with PS 2. PS had an independent effect on survival
since the hazard of death of patients with PS 2 was about two times
that of patients with PS 0–1 (HR: 1.853; 95% CI: 1.183–2.990). The
median survival for Group A patients with PS 0–1 and 2 were 9
(range, 0.5–29) and 1.5 (range, 0.5–16.5) months, respectively
(Wilcoxon’s test; P¼0.033); the corresponding values for Group B
patients were 7 (range, 0.5–24) and 1.5 (range, 0.5–23) months
(Wilcoxon’s test; Po0.001).
Compliance with the treatment
A total of 291 and 243 chemotherapy cycles were administered to
Group A (median three cycles; range 1–9) and Group B (median
three cycles; range, 1–8) patients, respectively. The median
interval between cycles in Groups A and B was 23 (range,
21–37) and 21 (range, 21–32) days, respectively. The median
dose intensity for patients randomised to Group A was
86mgm
 2week
 1 (range, 67–100) for CPT-11 and
598mgm
 2week
 1 (range, 296–667) for gemcitabine correspond-
ing to 86 and 90% of the planned CPT-11 and gemcitabine doses,
respectively. The median dose intensity of CPT-11 in patients
randomised to Group B was 99mgm
 2week
 1 (range, 58–100),
which corresponded to 99% of planned dose.
In total, 84 (29%) and 29 (12%) cycles were delayed in Groups A
and B, respectively, (P¼0.001). A total of 42 (14.4%) and 10 (4.1%)
cycles in Groups A and B, respectively, (Po 0.001) were delayed by
more than 7 days (median 11 days; range 8–41). Haematological
toxicity was the main reason for treatment delay (Group A, n¼35
cycles; Group B, n¼4 cycles; P¼0.006).
In all, 20 (7%) and 16 (6.6%) cycles of Groups A and B,
respectively, required dose reductions (P¼0.896), mainly because
of haematological toxicity (Group A, n¼9 cycles; Group B, n¼1
cycle; P¼0.018).
Toxicity
The haematological and non-haematological toxicities are sum-
marised in Table 3. Grade 3 and 4 neutropenia occurred in 21
(28%) and 13 (18%) patients in Groups A and B, respectively
(P¼0.180). A total of 128 (44%) and 73 (30%) cycles in Groups A
and B, respectively, required prophylactic rhG-CSF support
(P¼0.001). Febrile neutropenia occurred in three (4%) Group A
and eight (11%) Group B patients (P¼0.092); one patient in each
arm died of sepsis despite treatment with broad-spectrum i.v.
antibiotics and rhG-CSF support. Six (8%) patients randomised to
Group A developed grade 3 and 4 anaemia compared with no such
cases in Group B (P¼0.029). A total of 28 (37%) and 19 (27%)
Group A and B patients, respectively, who presented with
haemoglobin values p10.0gdl
 1, required at least one course of
recombinant human erythropoietin administration. Seven (9%)
patients of Group A and two (3%) patients of Group B developed
grade 3 and 4 thrombocytopenia (P¼0.106). No patients
developed clinical bleeding episodes requiring platelet transfusions
or hospitalisation.
Grade 3 and 4 nausea and vomiting were reported in five (7%)
and two (3%) of the Group A and B patients, respectively. The
incidence of diarrhoea (grade 2–4) was 25% in the combination
and 40% in the monotherapy arm (P¼0.169). Asthenia was
equally distributed across the groups; grade 3 and 4 asthenia was
reported in five (7.0%) and nine (13%) Group A and B patients,
respectively (P¼0.339). Severe asthenia was the reason for
treatment discontinuation in one patient randomised to CPT-11.
Other toxicities were mild (Table 3). There was no significant
difference in grade 3 and 4 haematological or nonhaematological
toxicities according to PS.
There were two Group A (one with grade 4 neutropeniaþsepsis
and one with grade 4 diarrhoeaþhypovolaemic shock) and three
Group B (one patient with grade 4 neutropeniaþsepsis, one
patient with sudden death occurring 9 days after the treatment
administration and one patient with acute bowel obstruction and
perforation) treatment-related deaths.
Quality of life
In all, 108 (73.5%) (Group A, n¼53 (69.7%); Group B, n¼55
(77.5%)) patients completed and returned questionnaires for
the evaluation of the impact of chemotherapy on the quality
of life.
Comparison between the treatment regimens showed that
patients treated with the combination regimen recorded better
responses to all questions than patients treated with CPT-11 alone.
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Figure 1 Kaplan–Meier estimate of the survival for Group A (CPT-
11þgemcitabine; dotted line) and Group B (CPT-11; continuous line)
patients.
Table 3 Haematological and nonhaematological toxicity of CPT-
11+GEM and CPT-11 alone, as second-line treatment in NSCLC patients
CPT-11+GEM (Group A) CPT-11 (Group B)
No. of pts No. of pts
Toxicity All grades Grade 3/4 All grades Grade 3/4
Haemoglobin 73 (26%) 6 (8%) 51 (68%) —
Neutrophils 44 (58%) 21 (28%) 23 (32%) 13 (18%)
Platelets 39 (51%) 7 (9%) 12 (17%) 2 (3%)
Febrile neutropenia 3 (4%) 3 (4%) 8 (11%) 8 (11%)
Nausea/vomiting 26 (34%) 5 (7%) 22 (20%) 3 (4%)
Diarrhoea 31 (41%) 12 (16%) 37 (52%) 15 (23%)
Mucositis 3 (4%) 1 (1%) 3 (4%) —
Asthenia 33 (59%) 6 (8%) 35 (49%) 9 (13%)
Allergic reactions 7 (9%) — — —
CPT-11 with or without gemcitabine second-line in NSCLC
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lFor patients who had completed both evaluations for cycles 1 and 3
(n¼80 patients), three of these differences indicated significant
improvements for the questions about: ‘general mood today’
(P¼0.014), ‘coughing’ (P¼0.033) and ‘intensity of symptoms’
(P¼0.034). Comparison of responses between cycles 1 and 6 for
the 35 patients who had completed both evaluations revealed
significant improvements in favour of the combination arm for
questions about ‘coughing’ (P¼0.003) and ‘general mood today’
(P¼0.006). The global quality of life score showed a trend in
favour of the combination arm in cycle 3 (P¼0.097) but not in
cycle 6 (P¼0.313).
DISCUSSION
The present multicentre, randomised, phase II study was designed
to evaluate whether a combination chemotherapy regimen, using
different anticancer drugs than those used in front-line treatment,
is better than single agent as second-line treatment of patients with
advanced NSCLC. Since the majority of patients had already
received docetaxel–cisplatin first-line therapy, CPT-11 in combi-
nation with gemcitabine was investigated as second-line treatment
(Kakolyris et al, 2002). The results clearly demonstrate that CPT-11
with gemcitabine resulted in a significantly higher objective
response rate and improved quality of life compared with CPT-
11, but failed to demonstrate any survival, duration of response
and TTP advantage.
The observed antitumour activity of CPT-11 alone, which
was in agreement with the results reported by Negoro et al
(Ferrigno and Buccheri, 2000) was poor. Conversely, the response
rate for the CPT-11/gemcitabine combination was satisfactory
and significantly higher than the obtained with CPT-11 alone.
In the Crino’s study, gemcitabine was active as second-line
treatment in patients with NSCLC (Crino et al, 1999). However,
in this study almost half of the patients had stage IIIA or IIIB
disease, and only 15% of them had received a taxaneþplatinum
as first-line chemotherapy. Conversely, in our study, all
patients had stage IV disease and had received docetaxel/platinum
front-line chemotherapy. In addition, the median time
interval from the last cycle of first-line chemotherapy was
3 months, suggesting that patients in the present study had a
severe probability of having chemoresistant disease. Preclinical
studies have demonstrated that there is a synergism between the
two drugs as already demonstrated in preclinical studies (Pei et al,
1997; Tsuruo et al, 1998; Schwartz et al, 2001); however, this
conclusion is difficult to drawn only on the basis of our clinical
observations.
The median overall survival was not statistically different
in patients treated with the combination regimen (9 months;
1-year survival: 24.5%) from those treated with CPT-11 alone
(7 months; 1-year survival: 29%). Only PS was found to have
a significant effect or survival (P¼0.049), since the risk of
death for patients with PS 2 was about twice that of patients with
PS 0–1 (HR¼1.853). It is interesting that the overall median
survival observed with CPT-11 alone was numerically similar with
that observed with single-agent docetaxel in the Shepherd’s
(Shepherd et al, 2000) and Fossella’s (Fossella et al, 2000) studies.
It would be of interest to compare CPT-11 as second-line
chemotherapy and best supportive care in patients with ad-
vanced/metastatic NSCLC pretreated with docetaxel/platinum
combination.
Until recently, the benefit of any second-line chemotherapy for
the treatment of patients with inoperable stage IIIB and IV NSCLC
was questionable. In 1997, the ASCO guidelines for second-line
treatment of NSCLC stated that ‘second-line treatment may be
appropriate for good PS patients for whom an investigational
protocol is not available or desired, or for patients who respond to
initial chemotherapy and then experience a long progression-free
interval off treatment’ (Am Soc Clin Oncol, 1997) The results
of the present study demonstrate no clear correlation between
the response to first-line chemotherapy and the probability
of response to second-line chemotherapy, since 12 responders
to second-line chemotherapy experienced SD or PD to first-line
chemotherapy; however, the low number of responding
patients necessitates the cautious interpretation of these results.
The selection of patients with advanced NSCLC who might
derive the greatest benefit from second-line chemotherapy
remains important. In a prospective randomised trial of second-
line docetaxel vs best supportive care, it could be demonstrated
that patients with weight loss greater than 10%, LDH, multiorgan
or liver involvement did not benefit from second-line chemother-
apy; conversely, refractoriness to front-line platinum-based
chemotherapy is not an independent prognostic factor (Shepherd
et al, 2001).
The optimal chemotherapy regimen for the second-line treat-
ment of advanced NSCLC remains elusive. Single-agent paclitaxel
(Socinski et al, 1999), docetaxel (Fossella et al, 2000; Shepherd et al,
2000) and gemcitabine (Baas et al, 1999; Rossi et al, 1999) have
been investigated in the second-line setting. In addition, several
phase II studies have evaluated different drug combinations in the
second-line setting (Androulakis et al, 1999; Herbst et al, 1999;
Herrero et al, 2000; Kosmas et al, 2001; Leu et al, 2001; Laack et al,
2002) The data from these studies strongly suggest that, although
response rates may be higher when a combination regimen is used
second line, the median overall survival ranges from 6 to 8 months,
which is not significantly different from that observed with single
agents.
In the present study, both single-agent CPT-11 and the CPT-11
in combination with gemcitabine were relatively well tolerated.
It is interesting that the toxicity profile of each treatment was not
very different in patients with PS 0–1 and 2. However, a
significantly higher number of chemotherapy cycles in the
combination than in the single-agent arm had to be delayed for
more than 7 days mainly due to haematological toxicity. The
higher incidence, although nonstatistically significant, of grade 3–
4 neutropenia in the combination arm as well as the increased
incidence of febrile neutropenia in the monotherapy arm should
be attributed to the more common use of rhG-CSF in the
combination regimen. There was one treatment-related death
due to sepsis in each arm. The other toxicities were mild and there
was no significant difference in their incidence between the two
treatment arms.
In conclusion, our results failed to demonstrate a survival
advantage of CPT-11þgemcitabine over CPT-11, although the
combination regimen was proved superior in terms of response
rate and quality of life. Recently, Fossella et al (2003) reported that
the docetaxelþCDDP regimen was superior in terms of overall
survival than the vinorelbineþCDDP combination. Therefore, an
increasing number of patients will be treated with front-line
docetaxel and cisplatin; for the patients who relapse after an
initial response or progress while receiving front-line docetax-
elþCDDP, the CPT-11þgemcitabine combination is a reasonable
second-line therapeutic option. Whether the combination of
second-line CPT-11/gemcitabine and sequential administration
of EGFR tyrosine kinase inhibitors could improve overall survival
of patients with advanced/metastatic NSCLC remains an attractive
question.
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The participating centres and investigators is provided in Table A1
Table A1 Participating centres and investigators
Centre Investigators
Dpt of Medical Oncology, University General Hospital of Heraklion, Crete V Georgoulias, Ch Kouroussis, D Mavroudis, N Androulakis
1st Dpt of Pulmonary Diseases, Hospital of Chest Diseases of Athens A Agelidou, E Papadakis
2nd Dpt of Pulmonary Disease, ‘Sismanoglion’ General Hospital of Athens F Apostolopoulou, X Tsiafaki, M Agelidou
2nd Dpt of Medical Oncology, ‘Theagenion’ Anticancer Hospital, Thessaloniki I Boukovinas, K Dimitriadis, I Stergiou, P Macrantonakis
1st Dpt of Pulmonary Diseases, ‘Sigmanoglion’ General Hospital of Athens Ph Palamidas, P Ziotopoulos
1st Dpt of Medical Oncology, ‘Agios Savvas’ Anticancer Hospital of Athens A Ardavanis, E Stavrinidis, G Rigatos, A Alexopoulos
8th Dpt of Pulmonary Diseases, Hospital of Chest Diseases of Athens O Anagnostopoulou, G Pavlakou, A Rapti
Medical Oncology Unit, ‘Laiko’ Hospital of Athens A Polyzos
Medical Oncology Unit, Dpt of Internal Medicine, Hospital of Pulmonary Diseases of Athens K Syrigos
Dpt of Pulmonary Diseases, ‘Papanikolaou’ General Hospital of Thessaloniki N Samaras
Dpt of Pulmonary Diseases, University General Hospital of Heraklion N Tzanakis
2nd Dpt of Medical Oncology, ‘Agii Anargyri’ Anticancer Hospital of Athens Th Giannakakis, S Papadouris
3rd Dpt of Pulmonary Diseases, Hospital of Chest Diseases of Athens F Christou
7th Dpt of Pulmonary Diseases, Hospital of Chest Diseases of Athens M Toubis
Medical Oncology Unit, 401 Military Hospital of Athens Ch Christophylakis
Dpt of Medical Oncology, General Hospital of Larissa A Athanasiadis
Dpt of Pulmonary Diseases, University of Athens, ‘Sotiria’ Hospital, Athens M Veslemes
Dpt of Internal Medicine, ‘Patision’ General Hospital of Athens E Tselepatiotis
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